TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02798523
Drug: Topical methylprednisolone (Advantan emulsion 0 /1%)
Normalized name: methylprednisolone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
Study: NCT02489630
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml/kg normal saline placebo
Study: NCT02489630
Drug: opiate analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
Study: NCT00025649
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025649
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02234011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01125891
Drug: ON 01910.Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
Study: NCT01821677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00538733
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)
Study: NCT04036617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
Study: NCT00813475
Drug: Basal bolus insulin regimen (tight glucose control)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal bolus insulin regimen
Study: NCT00813475
Drug: Basal bolus insulin regimen (standard control)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: basal bolus insulin regimen
Study: NCT03682796
Drug: TRPH-222
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by IV, 21-day Cycle
Study: NCT03118843
Drug: SOF/VEL/VOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study: NCT04283877
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 10 mg oral lactose tablet for all participants
Study: NCT03044665
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
Study: NCT03044665
Drug: Rosuvastatin plus ezetimibe
Normalized name: ezetimibe / rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
Study: NCT01982201
Drug: Tums 500 mg and 750 mg
Normalized name: calcium carbonate 500 MG [Tums]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01719575
Drug: Motilitone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01719575
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01790438
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01056107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injection daily
Study: NCT01790438
Drug: Human Insulin NPH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01790438
Drug: Oral Antihyperglycemic Medications (OAM)
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03270787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
Study: NCT01419990
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0634 300 mg oral capsules, qd, 10 days
Study: NCT01419990
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0634 450 mg oral capsules, qd, 10 days
Study: NCT01419990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules, qd, 10 days
Study: NCT02981472
Drug: Vitamin K Antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT02981472
Drug: Low Molecular Weight Heparin (LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00565500
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib capsules 200 mg bid for 1 week
Study: NCT00565500
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen tablets 600 mg tid for 1 week
Study: NCT03814447
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 300mg/m2/d
Study: NCT00565500
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules tid for 1 week
Study: NCT02669563
Drug: [18F]4F-MHPG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of \[18F\]4F-MHPG
Study: NCT02669563
Drug: [18F]3F-PHPG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of \[18F\]3F-PHPG
Study: NCT03340740
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar-appearing liquid to cetirizine oral suspension
Study: NCT00502060
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00502060
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04169828
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children in both the intervention and control group will receive Methotrexate dosed as prescribed by the attending rheumatologist
Study: NCT02158533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT00920543
Drug: FSC 100/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing
Study: NCT00920543
Drug: FSC 500/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing
Study: NCT04419506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
Study: NCT00395044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02842567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
Study: NCT01748994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02396862
Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
Study: NCT01606488
Drug: Florbetapir F 18 (18F-AV-45)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
Study: NCT03780517
Drug: BOS172738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04372589
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement.
Study: NCT03661385
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Addition of nitric oxide 20ppm into bypass circuit
Study: NCT01037712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00465569
Drug: cow's milk powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
Study: NCT01015443
Drug: Single low dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
Study: NCT01015443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
Study: NCT04334148
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral self administered tablet
Study: NCT03501212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Cream 2.5gr applied to both wrist
Study: NCT00796783
Drug: Cushing's syndrome confirmation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01508676
Drug: Placebo (2.3% DMSO solution)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02614794
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
Study: NCT02614794
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose twice daily
Study: NCT04498910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03426969
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01189773
Drug: ibuprofen and codeine
Normalized name: codeine and ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
Study: NCT01181960
Drug: Other Antipsychotics - New Starts
Normalized name: ANTIPSYCHOTICS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
Study: NCT00921921
Drug: HFA-BDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
Study: NCT00921921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
Study: NCT02573844
Drug: Proklama
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02573844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01272531
Drug: Mood stabilizer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: lithium or valproate
Study: NCT00069121
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.
Study: NCT00069121
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by one of two regimens, as specified in the arm description.
Study: NCT02354001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily for 12 week trial - lactose
Study: NCT01115712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (to match pioglitazone 30 mg) once daily
Study: NCT01115712
Drug: Comparator: Hyperinsulinemic Euglycemic Clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
Study: NCT02243566
Drug: MicardisPlus®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02319772
Drug: BCX4430
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02319772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01457339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule(s) for oral use taken once daily for 30 days
Study: NCT01925521
Drug: Part1 : OPS-2071
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose under fasted condition
Study: NCT01925521
Drug: Part1 : Placebo of OPS-2071
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose under fasted condition
Study: NCT01925521
Drug: Part2 : OPS-2071
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple twice-daily oral dosing for 5-7days
Study: NCT01925521
Drug: Part2 : Placebo of OPS-2071
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple twice-daily oral dosing for 5-7days
Study: NCT00097266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
Study: NCT01242527
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules (1g) daily for 12 weeks
Study: NCT01096667
Drug: Placebo to ertuglilflozin 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
Study: NCT01944215
Drug: Caffeine Tablet
Normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: effect of caffeine
Study: NCT01242527
Drug: omefas
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules (1g) + 2 placebo daily for 12 weeks
Study: NCT01242527
Drug: omefas
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules (1g) + 1 placebo daily for 12 weeks
Study: NCT01242527
Drug: omefas
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules (1g)daily for 12 weeks
Study: NCT02232789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oal dose placebo
Study: NCT00003937
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003937
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01919411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive 7 days of placebo after surgery.
Study: NCT00524303
Drug: FEC75
Normalized name: Fluorouracil, Epirubicin, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
Study: NCT03478683
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
Study: NCT03478683
Drug: Placebo to match FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
Study: NCT01690832
Drug: standard saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
Study: NCT02986451
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
Study: NCT04135781
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capetabine（1000 mg/m2 po, d1-14 bid ）
Study: NCT04538950
Drug: radioactive drug (tracer)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A radioactive drug (tracer) is used in the PET scan.
Study: NCT00853905
Drug: balanced salt solution BSS
Approvals — FDA: no, EMA: no, PMDA: no
Description: At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
Study: NCT00989703
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution, daily for 14 days
Study: NCT00989703
Drug: GLPG0259
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT00989703
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
Study: NCT02203682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet placebo for 12 weeks
Study: NCT02764619
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02764619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02246270
Drug: Intravesical Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bladder instillation
Study: NCT00184847
Drug: acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00184847
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00184847
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01317849
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.8mg
Study: NCT01317849
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg
Study: NCT01317849
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg
Study: NCT01317849
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500ug
Study: NCT01491958
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day +1, +3, and +6 and +11
Study: NCT01979510
Drug: MK-0663B
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0663B once daily for 8 days.
Study: NCT01979510
Drug: DOLOCAM PLUS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOLOCAM PLUS® once daily for 8 days.
Study: NCT01979510
Drug: Acetaminophen 500 mg
Normalized name: acetaminophen 500 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
Study: NCT00775307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 400 mg/day (24 weeks)
Study: NCT04359966
Drug: Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line therapy
Study: NCT02652429
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00656214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two divided dosage
Study: NCT00745030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 8 mg tablets
Study: NCT01614457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
Study: NCT02786537
Drug: SOF/LDV (sofosbuvir/ledipasvir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
Study: NCT02786537
Drug: EBR/GZR (elbasvir/grazoprevir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
Study: NCT04359953
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 2 x per day during 14 days
Study: NCT00275379
Drug: ERB-041
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00643045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03016715
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04715750
Drug: [18F]-PI2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
Study: NCT00337636
Drug: Medication to suppress the immune system
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression for 12 months post transplant
Study: NCT00622934
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo